SCHEMBL5046684

SCHEMBL5046684

CC(=O)c1ccc(C#Cc2ccc3c(c2)OCC(C)(C)CO3)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.61
KDM4E B2RXH2 2/20 0.46
RARB P10826 4/20 0.41
RARG P13631 4/20 0.41
RARA P10276 2/20 0.41
CYP26A1 O43174 1/20 0.41
CYP3A4 P08684 1/20 0.41
CRABP2 P29373 1/20 0.41
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAPT P10636 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046909 0.85 ACACB (0.55) ACACBRARBRARGRARACYP26A1
SCHEMBL9142407 0.84 KDM4E (0.63) ACACBKDM4EKMT2AMEN1NPC1
SCHEMBL5046845 0.82 ACACB (0.56) ACACBRARBRARGRARACYP26A1
SCHEMBL5046536 0.82 ACACB (0.54) ACACBKDM4ERARBRARGRARA
SCHEMBL5046911 0.81 ACACB (0.53) ACACBCYP3A4ALDH1A1MAPK1POLB
SCHEMBL5046583 0.80 HPGD (0.55) ACACBKDM4EMAPTALDH1A1TSHR
SCHEMBL5046835 0.77 ACACB (0.51) ACACBKDM4EKMT2AMEN1NPC1
SCHEMBL5043437 0.77 ACACB (0.51) ACACBKDM4ERARBRARGRARA
SCHEMBL5050543 0.76 HPGD (0.50) ACACBKDM4EMAPTALDH1A1TSHR
SCHEMBL256909 0.76 ACACB (1.00) ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP disclosed
EP-1682528-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US disclosed
WO-2005044814-A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113374-A1 Benzodioxepine derivatives BBOX1, ACOX1, ACOX3 ACACB 5/4885KDM4E 1100/4885RARB 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.